Photo by tirzavandijk from unsplash
Patients with psoriasis in difficult-to-treat areas experience substantial impairment in their welfare.1 Despite the remarkable efficacy of biologics, some patients may still suffer from residual disease in those sites affecting… Click to show full abstract
Patients with psoriasis in difficult-to-treat areas experience substantial impairment in their welfare.1 Despite the remarkable efficacy of biologics, some patients may still suffer from residual disease in those sites affecting their everyday life.2,3 Therefore, we aimed to analyze the percentage of "very much" and "a lot" responses, identified as "significant impact responses" (SIRs), to the Dermatology Life Quality Index (DLQI) questionnaire in patients under biologics or apremilast with resistant psoriasis in difficult-to-treat areas, mainly in cases with low DLQI scores, and to investigate the patients' desire for regimen switch.
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!